Comparison 9. Taxane‐platinum‐fluoropyrimidine combinations versus taxane‐platinum (without fluoropyrimidine).
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Overall survival | 3 | 482 | Hazard Ratio (Fixed, 95% CI) | 0.86 [0.71, 1.06] |
2 Tumour response | 3 | 482 | Odds Ratio (M‐H, Fixed, 95% CI) | 2.08 [1.37, 3.15] |
3 Progression‐free survival | 3 | 482 | Hazard Ratio (Fixed, 95% CI) | 0.74 [0.59, 0.93] |
4 Treatment‐related death | 3 | 482 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.95 [0.73, 5.17] |
5 Treatment discontinuation due to toxicity | 2 | 234 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.71 [0.79, 3.69] |